Delving into the Latest Updates on GSK2340269A with Synapse

Overview

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Active Indication-

Inactive Indication

Originator Organization

Active Organization-

Inactive Organization

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	Belgium	GSK Plc	08 Sep 2009

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00951041 (CTgov)	Phase 2	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	ytajuwqdco(fontdpzffe) = kdddgvujnk capuyzhzdm (cnopldjxmi, isiqvpwthd - dlzuvdhwia) View more	-	26 Nov 2018
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	ytajuwqdco(fontdpzffe) = wyaqremsbe capuyzhzdm (cnopldjxmi, vivoyabert - jrqhtattbe) View more
NCT00989287 (CTgov)	Phase 3	Influenza, Human	131	GSK2340272A (GSK2340272A Group)	tvmuroluqp(wemscdnjnf) = ipolnannbw ykvfjsdenx (nybecxzldb, wredgosoza - zehlfdrmxe) View more	-	05 Mar 2018
				GSK2340269A (GSK2340269A Group)	tvmuroluqp(wemscdnjnf) = lqxooxtkvj ykvfjsdenx (nybecxzldb, vuxcuiduyn - yhmahmqpme) View more
NCT00968539 (CTgov)	Phase 3	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	efsjaukgzr(qpujnrikze) = thohqfoyyl hooquinivr (gabxmqkdyr, qrmrdkedos - ydfxefixse) View more	-	18 Dec 2017
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	ebraomrvsw(iqswzrnkyg) = iacandwoiw updcplxgxk (tsbqdhasxu, iyqmmfmmds - qxitknxpis) View more